All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2019-12-13T15:43:35.000Z

The value of MRD in multiple myeloma

Dec 13, 2019
Share:

Bookmark this article

The Multiple Myeloma Hub are pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Mohamad Mohty, Saint-Antoine Hospital and Sorbonne University, Paris, FR, discusses the value of minimal residual disease (MRD) in multiple myeloma (MM).

In this video, Prof. Mohty discusses the use of MRD status in the treatment of patients with MM, highlighting an abstract presented by Luciano Costa during the ASH meeting, that showed it is feasible to use MRD-status to drive therapeutic decisions. However, it is important to note this trial was not a prospective randomized phase III trial. Prof. Mothy also notes the value of PET scanning as demonstrated in the CASSIOPET trial, and that MRD testing cannot replace PET scanning, rather they are complimentary. Lastly, Prof. Mohty comments on the potential use of mass spectrometry to test MRD-status, removing the requirement for bone marrow sample and giving very precise information.

The value of MRD in multiple myeloma

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox